SynthesisRMD open2020
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
Synthesis in RMD open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 11 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review.PharmacoEconomics · 2024Pooled it
- Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2024Pooled it
- Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.Advances in rheumatology (London, England) · 2024Pooled it
- Different biologics for biological-naïve patients with psoriatic arthritis: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis.BMJ open · 2022Pooled it
- Pooled it
- The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.Advances in rheumatology (London, England) · 2021Pooled it
- Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2021Pooled it
- The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis.Mediators of inflammation · 2021Pooled it
- A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.Frontiers in medicine · 2020Pooled it
- Article
- Fatty acid-binding protein 5 aggravates psoriasis and psoriasis-like disease through ferroptosis.Cell death and differentiation · 2026Article
- Research trends and priorities in the treatment of psoriatic arthritis from 2014 to 2024: A bibliometric and visualization study.Medicine · 2026Article
- Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study.Therapeutic advances in musculoskeletal disease · 2026Article
- Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis.Rheumatology advances in practice · 2026Article
- Psoriatic arthritis in transition: cytokine signaling, immune dysregulation, and therapeutic innovation.Inflammopharmacology · 2025Review
- Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.Advances in therapy · 2025Review
- High persistence of biologic therapy in patients with Psoriatic arthritis: a real-world evidence from a high-complexity hospital in Colombia.Frontiers in pharmacology · 2025Article
- Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.The Cochrane database of systematic reviews · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs are used in patients with psoriatic arthritis (PsA), but few studies directly compare their clinical efficacy. In such situations, network meta-analysis (NMA) can inform evidence-based decision-making.
objectiveTo evaluate the comparative efficacy and safety of approved bDMARDs in patients with PsA.
methodsBayesian NMA was conducted to compare the clinical efficacy of bDMARDs at weeks 12‒16 in bDMARD-naïve patients with PsA in terms of American College of Rheumatology (ACR) criteria, Psoriatic Arthritis Response Criteria (PsARC) and Psoriasis Area and Severity Index (PASI). Safety end points were evaluated in the overall mixed population of bDMARD-naive and bDMARD-experienced patients.
resultsFor ACR, all treatments except abatacept were statistically superior to placebo. Infliximab was most effective, followed by golimumab and etanercept, which were statistically superior to most other treatments. Ixekizumab 80 mg every 2 weeks (Q2W) was statistically superior to abatacept subcutaneous, apremilast and both regimens of ustekinumab; similar findings were observed for ixekizumab 80 mg Q4W. For PsARC response, ixekizumab did not significantly differ from other therapies, except for golimumab, infliximab and etanercept, which were superior to most other agents including ixekizumab. For PASI response, infliximab was numerically most effective, but was not statistically superior to ixekizumab, which was the next best performing agent. Analysis of safety end points identified few differences between treatments.
conclusionOur NMA confirms the efficacy and acceptable safety profile of bDMARDs in patients with active PsA. There were generally few statistically significant differences between most treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.